What is PreludeDx?
Founded in 2009 and leveraging technology licensed from the University of California San Francisco, PreludeDx is at the forefront of developing precision breast cancer tools. The company's core objective is to enhance patient outcomes and alleviate the financial burden on the healthcare system through innovative diagnostic technologies. This strategic financing round indicates a strong market belief in PreludeDx's approach to personalized medicine within the oncology sector.
How much funding has PreludeDx raised?
PreludeDx has raised a total of $20.4M across 2 funding rounds:
Debt
$350K
Other Financing Round
$20M
Debt (2020): $350K with participation from PPP
Other Financing Round (2022): $20M led by Evidity Health Capital
Key Investors in PreludeDx
Evidity Health Capital
Evidity Health Capital is a late-stage venture capital and growth equity firm that specializes in medical devices, in vitro diagnostics, and disruptive digital health. The firm focuses on private companies with commercialized products that require growth capital to achieve profitability.
PPP
Public-Private Partnership
What's next for PreludeDx?
With this substantial enterprise-level funding, PreludeDx is poised for significant expansion and further development of its diagnostic platforms. The investment is expected to accelerate the company's go-to-market strategies, enhance its research and development capabilities, and potentially broaden its market reach. This backing signals a critical growth phase for PreludeDx, enabling it to solidify its position in the competitive landscape of cancer diagnostics and personalized healthcare solutions.
See full PreludeDx company page
